Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Gains from Investment Securities (2022 - 2024)

Historic Gains from Investment Securities for Gossamer Bio (GOSS) over the last 3 years, with Q4 2024 value amounting to $52000.0.

  • Gossamer Bio's Gains from Investment Securities changed N/A to $52000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $52000.0, marking a year-over-year decrease of 9900.88%. This contributed to the annual value of $5.3 million for FY2024, which is 82975.21% up from last year.
  • According to the latest figures from Q4 2024, Gossamer Bio's Gains from Investment Securities is $52000.0.
  • In the past 5 years, Gossamer Bio's Gains from Investment Securities ranged from a high of $5.6 million in Q3 2024 and a low of -$726000.0 during Q3 2023
  • Its 3-year average for Gains from Investment Securities is $1.5 million, with a median of $52000.0 in 2024.
  • Examining YoY changes over the last 5 years, Gossamer Bio's Gains from Investment Securities showed a top increase of 86611.57% in 2024 and a maximum decrease of 86611.57% in 2024.
  • Gossamer Bio's Gains from Investment Securities (Quarter) stood at $3.0 million in 2022, then plummeted by 123.97% to -$726000.0 in 2023, then surged by 107.16% to $52000.0 in 2024.
  • Its Gains from Investment Securities was $52000.0 in Q4 2024, compared to $5.6 million in Q3 2024 and -$316000.0 in Q1 2024.